Dolutegravir (GSK1349572)是一种HIV整合酶抑制剂,IC50为2.7 nM,适度有效作用于抗Raltegravir的显著突变体Y143R, Q148K, N155H,和G140S/Q148H。
别名:GSK1349572
Dolutegravir (GSK1349572) is a novel potent integrase inhibitor with an IC50 of 2.7 nM in vitro. Dolutegravir (GSK1349572) is a compound for the treatment of HIV infection. Dolutegravir (GSK1349572) exhibited in vitro activity against most clinical isolates obtained from patients failing RAL-based therapy. In PBMC cell assay, Dolutegravir (GSK1349572) inhibited HIV integrase with the antiviral IC50=0.51 and IC90=2.0 nM. In MT-4 antiviral assays, potency shift extrapolated to 100% human serum was 75-fold providing PA-IC90=152 nM in PBMCs. Dolutegravir (GSK1349572) had a markedly different resistance profile as evidenced by limited cross-resistance to RAL-resistant molecular clones, by its in vitro activity against clinical isolates obtained from patients failing RAL-based therapy, and in selecting different mutations with low level FC during serial passage. In vitro experiments support the potential for Dolutegravir (GSK1349572) to have a higher genetic barrier to resistance when compared to 1st generation integrase inhibitors.
体外实验* | |
---|---|
细胞系 | MT-4 |
方法 | Growing MT-4 cells exponentially at a density of 500000 or 600000 /mL are infected with HIV-1 strain IIIB at a viral multiplicity of infection of 0.001 or a 50% tissue culture infective dose of 4 to 10. Then aliquoting the cells to 96-well plates in the presence of varying concentrations of S/GSK1349572. After incubation for 4 or 5 days, using the yellow tetrazolium MTT reagent [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] to determine antiviral activity by a cell viability assay that either measured bioluminescence with a CellTiter-Glo luminescent reagent or measured absorbance at 560 and 690 nm . |
浓度 | 0 to 10 μM |
处理时间 | 4 days or 5 days |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
体内实验* | |
---|---|
动物模型 | |
配制 | |
剂量 | |
给药处理 |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
分子量 | 419.38 |
分子式 | C20H19F2N3O5 |
CAS号 | 1051375-16-6 |
溶解性(25°C) | DMSO 60 mg/mL |
储存条件 |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.3845 mL | 11.9224 mL | 23.8447 mL |
5 mM | 0.4769 mL | 2.3845 mL | 4.7689 mL |
10 mM | 0.2384 mL | 1.1922 mL | 2.3845 mL |
小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 | |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km 系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
其他相关的Integrase产品 |
---|
Bictegravir Sodium
Bictegravir (GS-9883) Sodium 是一种新型的,高效的 HIV-1 整合酶抑制剂,专门针对 IN 链活性,IC50 值为 7.5 nM。 |
Lavendustin B
Lavendustin B inhibits HIV-1 integrase (IN) interaction with its cognate cellular cofactor lens epithelium-derived growth factor (LEDGF/p75). Lavendustin B is an inhibitor of Tyrosine Kinase and also a competitive inhibitor of glucose transporter 1 (Glut1). |
Bictegravir
Bictegravir (GS-9883) 是一种有效的新型HIV-1整合酶(Integrase)抑制剂,其IC50值为7.5 nM。 |
Raltegravir potassium
Raltegravir potassium (MK0518 potassium,雷特格韦钾) 是一种有效的 integrase 抑制剂,具有抗HIV活性,可用于AIDS的相关研究。 |
Dolutegravir sodium
Dolutegravir sodium (S/GSK1349572 sodium,度鲁特韦钠盐) 是一种高效的,具有口服活性的,第二代 HIV 整合酶(Integrase)链转移抑制剂,在 HIV-1 整合酶催化的链转移中的 IC50 值为 2.7 nM。 |
产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。
Copyright © 2010-2022 AbMole版权所有 沪ICP备16047849号 沪公网安备 31011502012228号